• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

    6/18/26 9:20:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email

    SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that President and Chief Executive Officer, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a Company corporate presentation during the BIO International Convention 2026, taking place June 22-25 in San Diego, California.

    As one of the biotechnology industry's premier global gatherings, BIO International Convention brings together thousands of executives, investors, innovators, policymakers and strategic partners to shape the future of healthcare. Daré's participation underscores the Company's growing leadership role in advancing innovation for women and accelerating the development of solutions that have historically been underrepresented in healthcare.

    "Women's health represents one of the largest and most underserved opportunities in healthcare today," said Ms. Johnson. "BIO International Convention provides an exceptional platform to engage with global industry leaders, investors and potential collaborators who share a commitment to advancing innovation and improving health outcomes. We are excited to highlight Daré's progress and discuss how our differentiated portfolio is positioned to address significant unmet needs while creating meaningful value for patients, partners and shareholders."

    Details of the Company's participation at BIO International Convention 2026 are as follows:

    Invest in San Diego Breakfast

    Date: Monday, June 22, 2026

    Time: 7:30 – 9:30 a.m. PT

    Location: IQHQ, 975 Waterfront Place, San Diego, California

    Ms. Johnson will participate as a featured speaker during the breakfast program, which highlights the San Diego region's life sciences ecosystem and brings together biotechnology executives, investors and industry stakeholders.

    WIB@BIO 2026 Executive Breakfast: Sparking Greatness — Leading Through Inspiration

    Date: Monday, June 22, 2026

    Time: 9:00 – 11:00 a.m. PT

    Location: RaDD (IQHQ), 6th Floor, 925 Waterfront Place, San Diego, California

    Ms. Johnson will join fellow biotechnology leaders for a discussion focused on leadership, mentorship and fostering innovation across the industry.

    BIO International Convention Corporate Presentation

    Date: Tuesday, June 23, 2026

    Time: 3:30 p.m. PT

    Location: Theater 4

    Ms. Johnson will discuss Daré Bioscience's corporate strategy, commercial and development portfolio and upcoming milestones, highlighting the Company's commitment to delivering impactful solutions that seek to address critical gaps in women's healthcare.

    Are We There Yet: The Road to Clinical Development in Women's Health

    Date: Wednesday, June 24, 2026

    Time: 4:15 – 5:15 p.m. PT

    Location: Room 26AB

    Ms. Johnson will join industry leaders and women's health advocates for a discussion examining the challenges and opportunities in advancing clinical development for women's health products. The session will explore pathways to accelerate innovation, improve patient access and address longstanding gaps in women's healthcare research and development.

    Investors and conference attendees interested in meeting with Daré management during the BIO International Convention are encouraged to contact the Company to arrange a meeting. For more information, please visit the convention website.

    ABOUT DARÉ BIOSCIENCE, INC.

    Daré Bioscience (NASDAQ:DARE) is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs. For decades, women have been told to "wait it out" or "live with it," while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré is working to change that. Learn more at darebioscience.com.



    CONTACT:

    Daré Bioscience Investor Relations

    innovations@darebioscience.com



    Primary Logo

    Get the next $DARE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Dare Bioscience with a new price target

    Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    6/30/21 9:55:24 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    SEC Filings

    View All

    SEC Form S-8 filed by Dare Bioscience Inc.

    S-8 - Dare Bioscience, Inc. (0001401914) (Filer)

    6/23/26 4:05:41 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    6/22/26 9:00:37 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    6/12/26 4:01:09 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rastetter William H

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    6/11/26 5:05:28 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Grossman Jessica D.

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    6/11/26 4:47:59 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matz Gregory W

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    6/11/26 4:52:10 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    View All

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Announces Executive Team and Board of Directors Changes

    SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

    1/26/24 4:30:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

    SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

    4/19/21 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

    SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that President and Chief Executive Officer, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a Company corporate presentation during the BIO International Convention 2026, taking place June 22-25 in San Diego, California. As one of the biotechnology industry's premier global gatherings, BIO International Convention brings together thousands of executives, investors, innovators, policymakers and strategic partners

    6/18/26 9:20:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules

    First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June

    6/4/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

    Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatmentsAward reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contra

    5/26/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

    Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week. Conference Call and Webcast Today at 4:30 p.m. ET "We are hosting our financial results and business update call from New York, in the middle of National Women's Health Week," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Daré was built on the conviction that women's health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribb

    5/14/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

    SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at ht

    5/7/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:36 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:35 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/12/21 5:13:06 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care